BLCO - Public offerings

Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. ("Bausch Health"), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the company’s outstanding common shares, the Bausch + Lomb Board has appointed four new directors, effective Aug. 5, 2026: Thomas J. Appio, CEO, Bausch Health Robert Chersi, founder of Chersi Services LLC, executive director and a pr

Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the "Notes"). In addition, the company announced that it has completed a partial refinancing of its credit agreement, and in connection with such refinancing, it has entered into a third amendment (the "Third Amendment") to its existing credit agreement providing for a $2.325

Revenues of $1.035 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $32 Million Adjusted EBITDA (non-GAAP)1 of $179 Million Revenues Grew 10% as Reported and 12% on a Constant Currency1 Basis Compared to the Second Quarter of 2022, Driven by Growth Across All Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP)1 by Approximately $18 Million and $25 Million, Respectively Raises Full-Year Revenue Outlook and Reaffirms Adjusted EBITDA (non-GAAP)1 Guidance Range Bausch + Lomb Corporation, (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2

Revenues of $931 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $90 Million Adjusted EBITDA (non-GAAP)1 of $141 Million Revenues Grew 5% as Reported and 8% on a Constant Currency1 Basis Compared to the First Quarter of 2022, Driven by Growth Across All Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP)1 by $31 Million and $14 Million, Respectively Bausch + Lomb Corporation, (TSX:BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results. "Bausch + Lomb delivered a strong firs

Fourth-Quarter 2022 Financial Results Revenues of $996 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $1 Million Adjusted EBITDA (non-GAAP)1 of $181 Million GAAP Cash Flow from Operations of $159 Million Reported Revenues Were in Line with Fourth-Quarter 2021 Reported Revenues, and Organic Revenues1,2 Grew 5%, Driven by Organic Growth1,2 Across All Segments Full-Year 2022 Financial Results Revenues of $3.768 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $6 Million Adjusted EBITDA (non-GAAP)1 of $720 Million GAAP Cash Flow from Operations of $345 Million Reported Revenues Were in Line with Full-Year 2021 Reported Revenues, a

Third-Quarter 2022 Financial ResultsRevenues of $942 MillionGAAP Net Loss Attributable to Bausch + Lomb Corporation of $18 MillionAdjusted EBITDA (non-GAAP)1 of $187 Million GAAP Cash Flow from Operations of $27 Million and $186 Million in the Third Quarter and Year-To-Date, RespectivelyThird-Quarter Reported Revenues Declined 1%, and Organic Revenues1,2 Grew 5%, Driven by Growth Across All SegmentsForeign Exchange Negatively Impacted Revenues by $55 Million in the Third QuarterRevised 2022 Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Ranges3, Primarily Due to Currency HeadwindsVAUGHAN, ON, Nov. 2, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (TSX:BLCO) ("Bausch + Lomb" or t

Second-Quarter 2022 Financial ResultsRevenues of $941 MillionGAAP Net Income of $5 MillionAdjusted EBITDA (non-GAAP)1 of $182 Million GAAP Cash Flow from Operations of $156 MillionReported Revenues Grew 1%, and Organic Revenues1,2 Grew 6%, Driven by Strong Performance in Vision Care and Surgical Segments Reaffirmed 2022 Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance RangesVAUGHAN, ON, Aug. 4, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (TSX:BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2022 financial results.